Portfolio company
Mozart Therapeutics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
The company develops CD8 T regulatory cell modulators to treat patients with autoimmune and inflammatory diseases including type 1 diabetes.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Modulari-T Biosciences
This company develops modular immune receptors and delivery vehicles to create cell and gene therapies for patients with cancer and autoimmune diseases.
Dualyx
This company develops immune-modulating therapies targeting regulatory T cells to treat patients with autoimmune diseases.
Abata Therapeutics
This company develops regulatory T cell therapies to treat patients with severe autoimmune and inflammatory diseases including progressive multiple sclerosis and type 1 diabetes.
Modulus Therapeutics
This company develops engineered NK-cell therapies for autoimmune disease patients using a generative design and rapid prototyping platform.
Egle Therapeutics
This biotechnology company develops precision medicines that modulate regulatory T cells to treat patients with autoimmune diseases and cancer.
T-Therapeutics
The company develops T cell receptor therapeutics and bispecific engagers for patients with cancer and autoimmune diseases.
Regcell
This biotechnology company develops regulatory T-cell therapies using an epigenetic reprogramming platform to treat patients with autoimmune diseases and inflammatory conditions.
TRexBio
This biotechnology company develops immunoregulatory medicines for patients with autoimmune and inflammatory diseases by decoding regulatory T cell function in human tissues.